Back to Results

Editas Medicine Inc (EDIT)

Featured in High-Beta Stocks Small-Cap Stocks

Editas Medicine, Inc. is a clinical-stage biotechnology company focused on developing genome editing medicines for serious diseases. The company is building a proprietary gene-editing platform using CRISPR-based technology and is advancing several programs across different therapeutic areas. Its lead program, EDIT-401, is a one-time treatment being developed to help lower LDL cholesterol by increasing LDL receptor activity in patients with hyperlipidemia. Editas is also working on therapies for sickle cell disease and transfusion-dependent beta thalassemia, along with in vivo gene-editing candidates for other cells and tissues. In addition, the company has a research collaboration with Juno Therapeutics to develop experimental alpha-beta T-cell medicines for solid and liquid tumors and autoimmune disease. Founded in 2013, the company is based in Cambridge, Massachusetts.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NASDAQ-EDIT
$2.76
-4.7% Downside
Fair
$5.78
99.2% Upside
Bargain
Fair
—
—
—
0.0%
August 5, 2026
-4.1x
101.0x
11.5x
442 M
338.7 M
3.8%
81.0%
-14.7
—
129.5%
Send a message
Valuation • Fair Value

Editas Medicine Inc (NASDAQ-EDIT) Fair Value by Valuation Model

Compare the primary fair value estimate for Editas Medicine Inc (NASDAQ-EDIT) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$2.76

Estimated downside of 4.7% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

$2.22

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

$3.49

Earnings power value estimate.

Comps Fair Value

$2.82

Comparable-company valuation reference.

Analyst Price Target

$5.78

Analysts imply upside of 99.2%.

How to read these valuation models

Use this section to compare the primary fair value estimate for Editas Medicine Inc (NASDAQ-EDIT) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Editas Medicine Inc (NASDAQ-EDIT)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

38.693 M

Current operating scale indicator.

Revenue Forecast

11.3 M

Forward revenue estimate.

EBITDA

-85.186 M

Current operating profitability reference.

EBITDA Forecast

-107.8 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Editas Medicine Inc (NASDAQ-EDIT) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Editas Medicine Inc (NASDAQ-EDIT)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

6

Mid-range quality score.

Beneish M-Score

3.55

Higher caution zone on this screen.

Altman Z-Score

-14.7

Lower score that deserves closer risk review.

FCF / Net Income

129.5%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Editas Medicine Inc (NASDAQ-EDIT). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Editas Medicine Inc (NASDAQ-EDIT)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 5, 2026

Days to Earnings

15

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Editas Medicine Inc (NASDAQ-EDIT), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Editas Medicine Inc (NASDAQ-EDIT) Stock Forecast & Technical Outlook

Review Editas Medicine Inc (NASDAQ-EDIT) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Buy

The 15-minute technical read for Editas Medicine Inc (NASDAQ-EDIT) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Editas Medicine Inc (NASDAQ-EDIT) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Editas Medicine Inc (NASDAQ-EDIT) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Neutral

The weekly technical read for Editas Medicine Inc (NASDAQ-EDIT) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Neutral

The monthly technical read for Editas Medicine Inc (NASDAQ-EDIT) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Editas Medicine Inc (NASDAQ-EDIT)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Buy

Based on the available recommendation mix, Editas Medicine Inc (NASDAQ-EDIT) has a Buy consensus, with 7 buy, 4 hold and 0 sell recommendations in the current data set.

Buy 7
Hold 4
Sell 0
FAQ • Fast Investor Answers

Editas Medicine Inc (NASDAQ-EDIT) Stock FAQ

Quick answers about Editas Medicine Inc (NASDAQ-EDIT) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$2.76
Estimated downside 4.7%
Valuation Rating
Overvalued
Estimated downside of 4.7%
Analyst Target
$5.78
Implied upside 99.2%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Editas Medicine Inc (NASDAQ-EDIT) is $2.76. This implies an estimated downside of 4.7% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 4.7% versus the current market price.

The available analyst price target for Editas Medicine Inc (NASDAQ-EDIT) is $5.78. The analyst target implies estimated upside of 99.2%.

The current financial health read for Editas Medicine Inc (NASDAQ-EDIT) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Editas Medicine Inc (NASDAQ-EDIT) is August 5, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Editas Medicine Inc (NASDAQ-EDIT) is -4.1x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Editas Medicine Inc is 442 M.

The current enterprise value listed for Editas Medicine Inc is 338.7 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Editas Medicine Inc is NASDAQ-EDIT, and the stock is listed on NASDAQ.

Editas Medicine Inc (NASDAQ-EDIT) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Editas Medicine Inc is 3.8%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Editas Medicine Inc is 81.0%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks on NASDAQ View more

Amgen Inc (AMGN) Amgen Inc (AMGN)
Gilead Sciences Inc (GILD) Gilead Sciences Inc (GILD)
Vertex Pharmaceuticals Inc (VRTX) Vertex Pharmaceuticals Inc (VRTX)
Regeneron Pharmaceuticals Inc (REGN) Regeneron Pharmaceuticals Inc (REGN)
Argenx NV ADR (ARGX) Argenx NV ADR (ARGX)
Revolution Medicines Inc (RVMD) Revolution Medicines Inc (RVMD)
Natera Inc (NTRA) Natera Inc (NTRA)
Alnylam Pharmaceuticals Inc (ALNY) Alnylam Pharmaceuticals Inc (ALNY)
BeOne Medicines AG DRC (ONC) BeOne Medicines AG DRC (ONC)
Biogen Inc (BIIB) Biogen Inc (BIIB)
Roivant Sciences Ltd (ROIV) Roivant Sciences Ltd (ROIV)
Moderna Inc (MRNA) Moderna Inc (MRNA)
BioNTech SE (BNTX) BioNTech SE (BNTX)
Insmed Inc (INSM) Insmed Inc (INSM)
Incyte Corporation (INCY) Incyte Corporation (INCY)
United Therapeutics Corporation (UTHR) United Therapeutics Corporation (UTHR)
Neurocrine Biosciences Inc (NBIX) Neurocrine Biosciences Inc (NBIX)
Genmab AS (GMAB) Genmab AS (GMAB)
BridgeBio Pharma Inc (BBIO) BridgeBio Pharma Inc (BBIO)
Ascendis Pharma AS (ASND) Ascendis Pharma AS (ASND)
Exelixis Inc (EXEL) Exelixis Inc (EXEL)
Madrigal Pharmaceuticals Inc (MDGL) Madrigal Pharmaceuticals Inc (MDGL)
Abivax SA ADR (ABVX) Abivax SA ADR (ABVX)
Biomarin Pharmaceutical Inc (BMRN) Biomarin Pharmaceutical Inc (BMRN)